huCART19
Phase 1Cell therapy
huCART19 is one of 54 biologic programs targeting CAR. It is currently in Phase 1.
2
Indications
4
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
121 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Ultomiris
AstraZenecaPhase 3
Felzartamab
BiogenPhase 3
Biological/vaccine
Vertex PharmaceuticalsPhase 3
Envarsus XR
UUniversity of Wisconsin, Madison
Phase 3
Zemplar
AbbViePreclinical
Cysteine Hydrochloride
NovartisPreclinical
Sensipar
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Radicava
ShionogiPreclinical
Jardiance
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Leukemia1 trial
Kidney Transplant1 trial
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06056102·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for huCART19. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pennsylvania